RECRUITING

Implementing a Contingency Management Program Addressing Methamphetamine Use For and With the People of Hawaii

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to use contingency management (CM) as an intervention tool to address methamphetamine use. The main objectives are to: * Gather effectiveness data on a pilot a CM program for participants in Hawaii who use methamphetamine following hospitalization due to traumatic injury * To assess participant perspectives on engaging with a CM program based at a Level 1 Trauma Center. Researches will assess both patient-reported and biologically-confirmed medium-term program effectiveness and conduct qualitative interviews with participants post-program. Participants will: * Visit a follow-up clinic up to three times per week to complete urinalysis following discharge from the trauma unit * Complete Treatment Effectiveness Assessments at 6 and 12-weeks * Engage in a qualitative interview at the end of the CM program

Official Title

Implementing a Contingency Management Program Addressing Methamphetamine Use For and With the People of Hawaii

Quick Facts

Study Start:2024-10-10
Study Completion:2025-09-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06532370

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Admitted trauma patients
  2. * Age greater than 18 years old
  3. * Urine drug screen positive for methamphetamines during the current hospitalization
  4. * Report at least weekly methamphetamine use
  5. * First methamphetamine use greater than 6 months prior to injury
  6. * Report at least 4 DSM-V Amphetamine-Type Substance Use Disorder symptoms (at least moderate disease)
  7. * Glasgow Coma Scale ≥13 upon arrival to the emergency department
  8. * Ability to understand and participate in study procedures
  9. * Ability to communicate in English
  1. * Active psychosis (reporting auditory or visual hallucinations)
  2. * Under ongoing cardiorespiratory monitoring
  3. * Evidence of moderate or severe traumatic brain injury
  4. * Patients who are known to be pregnant
  5. * Prisoner
  6. * Individuals incarcerated at the time of their hospitalization
  7. * Individuals lacking capacity to provide, or are otherwise unable or unwilling to provide written informed consent

Contacts and Locations

Study Contact

Nicholas R Schumann, Clinical Psychologist
CONTACT
(808) 691-7024
nschumann@queens.org
Karen Ng, RN
CONTACT
808-691-4729
kng@queens.org

Principal Investigator

Todd Seto, MD
STUDY_CHAIR
The Queens Medical Center

Study Locations (Sites)

The Queen's Medical Center
Honolulu, Hawaii, 90813
United States

Collaborators and Investigators

Sponsor: Queen's Medical Center

  • Todd Seto, MD, STUDY_CHAIR, The Queens Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-10-10
Study Completion Date2025-09-30

Study Record Updates

Study Start Date2024-10-10
Study Completion Date2025-09-30

Terms related to this study

Additional Relevant MeSH Terms

  • Contingency Managment
  • Methamphetamine Use Disorder